NASDAQ | VICL: 0.60  +0.00
investors
Investors

News Releases

DateSubject
September 3, 2015 Vical to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
August 19, 2015 FDA Grants Qualified Infectious Disease Product (QIDP) Designation to VL-2397, Vical's Antifungal Product Candidate
July 30, 2015 Vical Reports Second Quarter 2015 Financial Results and Progress in Key Development Programs
July 23, 2015 Vical Announces News Release and Conference Call Schedule for Second Quarter 2015 Financial Results
June 22, 2015 Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine
May 21, 2015 Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients
May 8, 2015 Vical Reports First Quarter 2015 Financial Results and Progress in Key Development Programs
May 1, 2015 Vical Announces News Release and Conference Call Schedule for First Quarter 2015 Financial Results
April 22, 2015 Vical to Manufacture HIV Vaccines for Clinical Evaluation by Public-Private Partnership Initiative
April 21, 2015 Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference
March 25, 2015 Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas
March 5, 2015 Vical to Present at the 27th Annual ROTH Conference
February 26, 2015 Vical Reports Fourth Quarter 2014 Financial Results and Progress in Key Development Programs
February 19, 2015 Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2014 Financial Results
February 9, 2015 Vical to Present at the Leerink Global Healthcare Conference
January 14, 2015 Vical and AnGes Announce Collaboration to Develop Therapy for Ebola Virus Disease

AnGes Ebola Antibody Therapy

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.